Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19626312 | 0.84 | MEN1 (0.33) | ALDH1A1KDM4ESMN1; SMN2PKM | |
| SCHEMBL19626313 | 0.78 | KDM4E (0.35) | ALDH1A1KDM4ESMN1; SMN2PDE10AGAA | |
| SCHEMBL14341758 | 0.69 | ADORA2A (0.32) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL19677954 | 0.69 | MEN1 (0.35) | ALDH1A1KDM4ESMN1; SMN2PKMPDE10A | |
| SCHEMBL5484430 | 0.66 | MEN1 (0.41) | HTT | |
| SCHEMBL19036911 | 0.66 | KDM4E (0.45) | ALDH1A1KDM4ESMN1; SMN2PKMPDE10A | |
| SCHEMBL19680298 | 0.64 | KDM4E (0.62) | ALDH1A1KDM4ESMN1; SMN2PKMMAPT | |
| SCHEMBL12758040 | 0.63 | PDE10A (0.38) | ALDH1A1KDM4ESMN1; SMN2PKMPDE10A | |
| SCHEMBL14525123 | 0.63 | HTT (0.38) | ALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL20348409 | 0.62 | HSD17B10 (0.41) | ALDH1A1KDM4ESMN1; SMN2PKMPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - BIOTECH INVESTMENTS, INC. (PT) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, PARK7 | ALDH1A1 1325/4885KDM4E 710/4885SMN1; SMN2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.